Renexxion
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
325 Sharon Park Dr # 303, Menlo Park, Ca...Phone Number
(650) 924-9895Website
www.renexxion.comRevenue
<$5 MillionIndustry
About Renexxion
Renexxion Org Chart
Is Renexxion your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Renexxion had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Renexxion
Renexxion, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Renexxion is spiking on competitors!
Funding: Get notified immidiatlly once Renexxion has new funding data
Check if Renexxion has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Renexxion launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Renexxion recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Renexxion as Masked Content
Find more new buyers
Compare Similar Companies to Renexxion
Compare insights from companies similar to Renexxion, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Renexxion is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Renexxion is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Renexxion.
Renexxion Tech Stack
A closer look at the technologies used by Renexxion
Renexxion News & Media
Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis
Dr Falk and Renexxion commit to late-stage development following naronapride’s positive P2b results in gastroparesis, a disease with high unmet need.Dr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
Positive results from global Phase 2b trial evaluating the efficacy, safety, and tolerability of naronapride in adults with gastroparesisDr. Falk Pharma and Renexxion announce positive results on naronapride in gastroparesis from the global phase 2b MOVE-IT trial
Positive P2b trial results on naronapride show significant, meaningful impact on gastroparesis symptoms; with favorable safety and tolerability profiles.Dr. Falk Pharma and Renexxion Announce Late-Breaker Oral Presentation of Global Phase 2b Gastroparesis Results at Digestive Disease Week (DDW) 2026
Dr Falk and Renexxion selected for late-breaking oral presentation at this year’s DDW, for data from global P2b study of naronapride in gastroparesis.
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Renexxion
Renexxion, Inc. is a US-based biotechnology company focused on delivering innovative drugs for patients with high unmet needs in gastrointestinal disorders. Their primary product, Naronapride, is designed to address these conditions effectively. The company operates a wholly owned subsidiary in Ireland, Renexxion Ireland Limited, and is led by a te... Read More